Drug Pricing Strategies
Expert articles and analysis related to drug pricing strategies.
AI Summary — Last 7 Days
Over the past week, the dynamics surrounding drug pricing strategies have intensified, particularly as CMS threatens to block enrollment in Medicare drug plans for Elevance Health, signaling potential shifts in access and competition within the Medicare landscape. Amidst this, a new Peterson-KFF report highlights rising prescription drug costs and the need for greater price transparency as vital issues affecting affordability, which are becoming increasingly critical for Accountable Care Organizations (ACOs) and their strategies to manage population health. These developments occur within the context of an evolving Medicare drug negotiation program, with stakeholders bracing for implications on care delivery models and financial sustainability in light of persistent cost pressures, as noted by CMS's assessment of insurers.
Related Articles
Signs Of ‘Most Favored Nation’ Impact: What Experts Are Looking For
Signs Of ‘Most Favored Nation’ Impact: What Experts Are Looking For Health Affairs
STAT+: U.K. to take another look at cost-effectiveness of Alzheimer’s drugs
Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective.
STAT+: Novartis picks up experimental breast cancer therapy for $2B
Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based Synnovation Therapeutics.
Generic Launch Market Entry Study
This study from Wakely, an HMA Company, created for the Pharmaceutical Care Management Association (PCMA), analyzes what happens when a small‑molecule brand drug loses patent protection—how quickly ge...
STAT+: Trump’s Medicare director seeks to rein in expectations for TrumpRx
The Trump administration is counting on its drug pricing efforts to help with the midterm elections.
STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.
STAT+: Pharmalittle: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more
Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study
Mark Cuban says Trump Rx saving people 'a lot of money' on some drugs
Mark Cuban says Trump Rx saving people 'a lot of money' on some drugs Health Leaders Media
Opinion: There is a successor to 340B lurking on the horizon
The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully reform the health care system.
Experts: Weakening Vaccine Liability Protections Would Increase Prices And Reduce Innovation
Experts: Weakening Vaccine Liability Protections Would Increase Prices And Reduce Innovation Health Affairs